Lv1
10 积分 2024-03-27 加入
Fibroblast growth factor receptors as treatment targets in clinical oncology
1天前
待确认
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
10天前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
10天前
已完结
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
10天前
已完结
Antibody–drug conjugates in gynaecological cancers: opportunities and challenges
12天前
已完结
Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis
16天前
已完结
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib
19天前
已完结
c-Kit—A hematopoietic cell essential receptor tyrosine kinase
19天前
已完结
Incidence and management of esophageal cancer recurrence to regional lymph nodes after curative esophagectomy
23天前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
24天前
已完结
皖公网安备34019202002308
